BrevaRex MAb-AR20.5 is under clinical development by OncoQuest and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BrevaRex MAb-AR20.5’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BrevaRex MAb-AR20.5 overview
BrevaRex MAb-AR20.5 is under development for the treatment of pancreatic cancer. It is administered through intravenous route. The drug candidate is an antibody generated against the tandem repeat protein backbone of the tumor associated antigen MUC1. It was also under development for the treatment of breast cancer, multiple myeloma, advanced malignancies and solid tumors. It was also under development for the treatment of in China pancreatic cancer.
OncoQuest overview
OncoQuest., is a developer of immunotherapeutic products for the treatment of cancer. The company is headquartered in Canada.
For a complete picture of BrevaRex MAb-AR20.5’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
